Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Targeting of Gasdermin D-Mediated Pyroptosis to Attenuate Joint Inflammation in Rheumatoid Arthritis

NCT07534332 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT07534332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07534332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Targeting of Gasdermin D-Mediated Pyroptosis to Attenuate Joint Inflammation in Rheumatoid Arthritis
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
April 30, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammation, obesity, rheumatoid arthritis